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FSAP reduces risk of repair
Overenthusiastic repair of 
damaged blood vessels 
could cause a fatal block-
age. Sedding et al. (page 
2801) report that the 
  normal repair-restricting 
function of factor VII ac-
tivating protease (FSAP) is 
disrupted by a common 
mutation. People carrying 
the mutation might thus be more at risk of vessel narrowing.
Approximately 5% of the population carries an FSAP polymorphism 
linked to cardiovascular disease. The authors’ previous in vitro evidence 
suggested that wild-type FSAP, a plasma protein, limits vessel repair processes 
in part by inactivating PDGF-BB—a growth factor which promotes the 
proliferation and migration of blood vessel wall cells during repair.
The team isolated and characterized the mutated form of FSAP and 
discovered that although its ability to bind PDGF-BB was unaltered, it 
failed to cleave the protein efficiently. Wild-type human FSAP reduced 
vascular cell proliferation and accumulation at sites of injury in a 
mouse model—most likely by reducing PDGF-BB activity. The 
mutant protein, however, provided no such restraint, suggesting that people possessing the 
mutation might generate excessive scar tissue during vessel repair.
Vessel narrowing occasionally recurs after surgical repair. If, as the team suspects, recurrence 
correlates with the FSAP polymorphism, then screening cardiovascular patients for the 
mutation might identify those at risk. 
Dynamic DCs of the gut
Dendritic cells (DCs) stretch finger-like extensions 
into the gut to capture bacteria. But, according 
to Chieppa et al. (page 2841), it is the gut 
epithelial cells that first recognize the bacteria 
and then give DCs the tip-off.
Regular sampling of gut bacterial antigens 
by the immune system is necessary for 
maintaining tolerance to commensal bacteria 
and for defending against pathogens. DCs 
gather bacterial antigens using their extensions, 
but Chieppa et al. show that these extensions 
are not a constitutive feature of gut DCs.
Treatment of mice with antibiotics reduced 
the number of DC extensions in the small bowel, 
whereas oral infection of mice with Salmonella 
increased their numbers. DC extensions are thus 
dependent on the presence of the bacteria 
themselves. Indeed, live imaging using intravital 
microscopy showed that DC extensions begin to 
emerge from the gut wall following bacterial 
exposure and remain protruded for 10–40 min 
before retracting with their quarry.
Recognition of bacteria by innate immune 
cells is often dependent on Toll-like receptors 
(TLRs). Recent studies reveal that gut epithelial 
cells also have TLRs, and the group show here 
that mice lacking specific epithelial but not DC 
TLRs failed to extend DC processes across their 
gut wall in response to the relevant bacterial 
stimuli. Although the team does not yet know 
how epithelial cells alert the DCs, the gut barrier 
function of the epithelial cells makes them the 
perfect choice to be the first to perform identity 
checks on gut bacteria. 
Get Syk and get cycling
Rampant proliferation of pre–B cells in leukemia can be caused by overly 
active proto-oncogenes such as c-Myc. Wossning et al. (page 2829) now 
discover that this c-Myc surplus is driven by a tyrosine kinase called Syk. But 
even with lots of c-Myc, pre–B cells still need Syk to cycle.
B cell proliferation and differentiation must be tightly controlled to 
avoid the release of immature, nonfunctional cells into the circulation. 
The proliferation is driven by the pre–B cell receptor (pre-BCR), which 
activates Syk. Syk’s role in proliferation is murky: it is overexpressed in 
some types of lymphoma and leukemia cells, yet it activates a known 
tumor suppressor and is down-regulated in certain malignant cancers.
To sort through this confusion, Wossning et al. overexpressed Syk in pre–B 
cells, which transformed the cells into an overproliferative, undifferentiated state. 
A Syk-specific inhibitor reversed this phenotype. The team thus concludes that 
Syk is a proto-oncogene rather than tumor suppressor, at least in this cell type.
The group also found that Syk promoted c-Myc expression. The addition of 
more c-Myc was all that was needed to transform pre–B cells, yet this 
transformation was reversed by Syk inhibition. Furthermore, c-Myc expression 
did not transform pre–B cells that lacked the pre-BCR. Together, these results 
indicate that Syk must be turning on other necessary proliferative or survival 
signals—perhaps Bcl-2 family members—in addition to c-Myc.
The finding that transformation resulting from either too much Syk or too 
much c-Myc can both be blocked with a Syk inhibitor suggests that a variety 
of B cell proliferative disorders might respond to this type of treatment. 
Dendritic cells (green) reach their finger-like 
protrusions past the gut epithelia to catch bacteria.
After vascular injury, repair is restricted in the 
presence of FSAP (right) to prevent narrowing 
of the blood vessel.